登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Nature，4月21日，Developing therapeutic monoclonal antibodies at pandemic pace》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-04-22

  • Developing therapeutic monoclonal antibodies at pandemic pace

    Brian Kelley

    Nature Biotechnology (2020)

    Outbreaks of emerging infectious diseases have become increasingly common in recent decades. Epidemics have spread across the globe, including AIDS, H1N1 influenza and most recently coronavirus disease (COVID-19). In the face of a pandemic infectious disease outbreak, new approaches should be explored to enable the most rapid evaluation of antibodies for passive immunization or treatment. The fastest timeline from discovery to clinical evaluation of novel recombinant antibodies for medical use has been a focus of the biopharmaceutical industry for decades. For potentially life-saving therapies, the benefits of the earliest clinic testing should translate to accelerated pivotal trial testing and maximal patient benefit.

  • 原文来源：https://www.nature.com/articles/s41587-020-0512-5
7浏览量
原文链接
相关报告

  • 《Nature，4月8日，Humanity tested》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-09
    • The world needs mass at-home serological testing for antibodies elicited by SARS-CoV-2, and rapid and frequent point-of-care testing for the presence of the virus’ RNA in selected populations. How did we end up here? Two ways. Gradually, then suddenly. Ernest Hemingway’s passage is a fitting description for humanity’s perception of the exponential growth of COVID-19 cases and deaths (Fig. 1). The worldwide spread of a highly infectious pathogen was only a matter of time, as long warned by many epidemiologists, public health experts, and influential and prominent voices, such as Bill Gates. Yet most of the world was unprepared for such a pandemic; in fact, most Western countries (prominently the United States1) fumbled their response for weeks. Singapore, Hong Kong and Taiwan have shown the world that, to contain the propagation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), governments need to quickly implement aggressive testing (by detecting the viral RNA through polymerase chain reaction (PCR)), the isolation of those infected and the tracing and quarantining of their contacts, while educating their citizens about the need for physical distancing and basic public health measures (in particular, frequent hand-washing and staying at home if feeling unwell).
    72浏览量
    原文链接

  • 《Medicalxpress，1月21日，Study: Omicron evades some but not all monoclonal antibodies》
    • 来源专题：COVID-19科研动态监测
    • 编译者：YUTING
    • 发布时间：2022-02-10
    • Several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the omicron variant now sweeping across the United States, researchers reported Jan. 19 in the journal Nature Medicine. The laboratory study, led by researchers at Washington University School of Medicine in St. Louis, Missouri, tested five antibody combinations including precursor antibodies discovered at Vanderbilt University Medical Center that subsequently were optimized by AstraZeneca and which were authorized for emergency use in patients last month. Several antibodies, including those in clinical use by Celltrion, Regeneron and Eli Lilly, completely lost the ability to neutralize the omicron variant in cell culture, whereas the antibodies discovered at VUMC had a reduced neutralizing ability, and an antibody developed by Vir Biotechnology was minimally affected, the study found. "Omicron escapes recognition by several of the monoclonal antibodies that are being used for therapy," said James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, whose team discovered the monoclonal antibodies later optimized by AstraZeneca into a long-acting antibody combination called Evusheld.
    7浏览量
    原文链接